SEFA-1024
Small molecule
Also known as NST-1024
Evidence outlook · results not reported
NCT05889156 · High Triglycerides
The lead study's design has limits that temper confidence (see the rationale below), and its results have not been reported. This tier describes the design, not an outcome.
NCT05889156: The trial is randomized and blinded with a placebo comparator and measures triglyceride change, the standard disease-defining outcome for this condition, but no results are posted yet, so whether the drug lowered triglycerides is still unknown.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05889156 NCT05889156 · High Triglycerides The trial is randomized and blinded with a placebo comparator and measures triglyceride change, the standard disease-defining outcome for this condition, but no results are posted yet, so whether the drug lowered triglycerides is still unknown. Registry: NCT05889156 | 2 | Evaluate the efficacy of NST-1024 by percentage change in TG (4 weeks) 2025-03-18 | Results not posted; external-source review pending | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (1)
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
This drug's own stage for Severe Hypertriglyceridemia: Stage not on record. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| SEFA-1024: this drug | Stage not on record | Small molecule | Hepatic triglyceride/VLDL synthesis pathway | Partial signal | No reviewed efficacy summary in this indication | |
| Icosapent Ethyl (Vascepa) | Approved | Small molecule | Omega-3 fatty acid (EPA) | Reliable signal | NCT01047683: Difference Between AMR101 (Ethyl Icosapentate) and Placebo Treatment Groups in Triglyceride Lowering Effect (baseline and 12 weeks): AMR101 (Ethyl Icosapentate) - 2 g/Day -7 Percent change from baseline (IQR -30.1 to 18.6) | AMR101 (Ethyl Icosapentate) - 4 g/Day -26.6 Percent change from baseline (IQR -41.1 to 0) vs Placebo 9.7 Percent change from baseline (IQR -19.2 to 42.3) | |
| Olezarsen (Tryngolza) | Approved | RNA / oligonucleotide | APOC3 | Reliable signal | NCT05552326: Percent change in fasting triglycerides from baseline vs placebo at Month 6 (CORE2-TIMI 72b, n=444): olezarsen 50 mg -49.2% (95% CI -59.7 to -38.8, p<0.001); olezarsen 80 mg -54.5% (95% CI -65.1 to -44, p<0.001) NCT05079919: Placebo-adjusted LSM % change in fasting triglycerides at 6 months (CORE-TIMI 72a, NCT05079919, n=617): olezarsen 50 mg -62.9% (95% CI -72.2 to -53.6, p<0.001); olezarsen 80 mg -72.2% (95% CI -81.4 to -63.1, p<0.001). | |
| Omega-3-Acid Ethyl Esters (Lovaza) | Approved | Small molecule | Triglyceride metabolism | not yet graded | No reviewed efficacy summary in this indication | |
| Omega-3-Acid Ethyl Esters A (Omtryg) | ApprovedUS marketing discontinued | Small molecule | Triglyceride synthesis / VLDL | not yet graded | No reviewed efficacy summary in this indication | |
| DR10624 | Phase 3 | Protein / enzyme therapeutic | GLP-1R; GCGR; FGF21R | Partial signal | NCT06555640: Median triglyceride reduction: 74.5% (12.5 mg), 66.2% (25 mg), 68.9% (50 mg titration) vs 8.0% with placebo | |
| Pegozafermin | Phase 3 | Protein / enzyme therapeutic | FGFR1c/2c/3c–β-Klotho agonist | Partial signal | No reviewed efficacy summary in this indication | |
| Pemafibrate (Parmodia) | Phase 3 | Small molecule | PPAR-alpha | Partial signal | NCT03011450: Percent Change in Fasting TG From Baseline to Week 12 (12 Weeks): K-877 -58.89% (IQR -71.69 to -38.42) vs Placebo -22.94% (IQR -43.98 to 9.67) NCT03001817: Percent Change of Fasting Triglyceride(TG) Levels From Baseline to Week 12 (12 Weeks): K-877 -56% (IQR -72.08 to -32.4) vs Placebo -7.97% (IQR -44.78 to 49.87) | |
| Plozasiran (Redemplo) | Phase 3 | RNA / oligonucleotide | APOC3 | Partial signal | No reviewed efficacy summary in this indication | |
| Volanesorsen (Waylivra) | Phase 3 | RNA / oligonucleotide | APOC3 mRNA | Partial signal | NCT02300233: Percent Change in Fasting Triglycerides (TG) From Baseline to Month 3 (Baseline to 3 months): Volanesorsen Total -71.2% (95% CI -79.3 to -63.2) vs Placebo -0.9% (95% CI -13.9 to 12.2) | |
| HRS-7249 | Phase 2 | RNA / oligonucleotide | APOC3 | not yet graded | No reviewed efficacy summary in this indication | |
| ION775 | Phase 2 | RNA / oligonucleotide | APOC3 | not yet graded | No reviewed efficacy summary in this indication | |
| Solbinsiran | Phase 2 | RNA / oligonucleotide | ANGPTL3 | not yet graded | No reviewed efficacy summary in this indication | |
| CS-121 | Phase 1 | Gene therapy / editing | APOC3 | not yet graded | No reviewed efficacy summary in this indication | |
| CTX310 | Phase 1 | Gene therapy / editing | ANGPTL3 | not yet graded | No reviewed efficacy summary in this indication | |
| GC304 | Phase 1(overall) | Gene or cell therapy (subtype unspecified) | LPL (lipoprotein lipase) gene | not yet graded | No reviewed efficacy summary in this indication | |
| Extended-Release Niacin (Niaspan) | Discontinued | Small molecule | GPR109A (HCAR2) | not yet graded | No reviewed efficacy summary in this indication | |
| Omega-3-Carboxylic Acids (Epanova) | Discontinued | Small molecule | Peroxisome proliferator-activated receptor alpha (PPARα); also acts as a lipid-modifying agent via free fatty acid receptor | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.